Evidence map›Paper›PMID 32556671›Full record

ReviewHeart failure reviews2022

Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?

Andrea Lorenzo Vecchi, Raffaele Abete, Jacopo Marazzato, Attilio Iacovoni, Andrea Mortara, Roberto De Ponti, Michele Senni

Abstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Contemporary Insights into LMNA Cardiomyopathy.Current cardiology reports · 2025
    Review
  6. Neurohumoral Activation in Heart Failure.International journal of molecular sciences · 2023
    Review
  7. Sudden cardiac death prevention in the era of novel heart failure medications.American heart journal plus : cardiology research and practice · 2023
    Review
  8. Article
  9. Article
  10. Sacubitril/Valsartan in the Management of Heart Failure Patients with Cardiac Implantable Electronic Devices.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2021
    Review
  11. Will introduction of ARNI reduce the need of device therapy in heart failure with reduced ejection fraction?The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Andrea Lorenzo VecchiDepartment of Heart and Vessels, Ospedale di Circolo and Macchi Foundation, University of Insubria, Varese, Italy. andrealorenzo.vecchi@libero.it.ORCID 0000-0001-8595-0651
Raffaele AbeteDepartment of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Jacopo MarazzatoDepartment of Heart and Vessels, Ospedale di Circolo and Macchi Foundation, University of Insubria, Varese, Italy.
Attilio IacovoniCardiovascular Department & Cardiology Unit, Papa Giovanni XXIII Hospital-Bergamo, Bergamo, Italy.
Andrea MortaraDepartment of Cardiology, Policlinico di Monza, Monza, Italy.
Roberto De PontiDepartment of Heart and Vessels, Ospedale di Circolo and Macchi Foundation, University of Insubria, Varese, Italy.
Michele SenniCardiovascular Department & Cardiology Unit, Papa Giovanni XXIII Hospital-Bergamo, Bergamo, Italy.
University of Insubria · ITFondazione Lanza · ITOspedale Papa Giovanni XXIII · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The remarkable scientific progress in the treatment of patients with heart failure (HF) and reduced ejection fraction (HFrEF) has more than halved the risk of sudden cardiac death (SCD) in this setting. However, SCD remains one of the major causes of death in this patient population. Beyond the acknowledged role of beta blockers and inhibitors of the renin-angiotensin-aldosterone system (RAAS), a new class of drugs, the angiotensin receptor neprilysin inhibitors (ARNI), proved to reduce the overall cardiovascular mortality and, more specifically, the risk of SCD in HFrEF patients. The mechanism by which ARNI may reduce the mortality connected with harmful ventricular arrhythmias is not utterly clear. A variety of direct and indirect mechanisms have been suggested, but a favorable left ventricular reverse remodeling seems to play a key role in this setting. Furthermore, the well-known protective effect of implantable cardioverter-defibrillator (ICD) has been debated in HFrEF patients with non-ischemic cardiomyopathy (NICM) arguing against the role of primary prevention ICD in this setting, particularly when ARNI therapy is considered. The purpose of this review was to provide insights into the SCD mechanisms involved in HFrEF patients together with the current role of electrical therapies and new drug agents in this setting. Graphical abstract.

Indexed as

Heart FailureAminobutyratesAngiotensin Receptor AntagonistsArrhythmias, CardiacBiphenyl CompoundsHumansReceptors, AngiotensinStroke VolumeTetrazolesValsartanAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsReceptors, AngiotensinTetrazolesValsartanAngiotensin receptor neprilysin inhibitorsHeart failure reduced ejection fractionImplantable cardioverter-defibrillatorSacubitril/valsartanSudden cardiac deathVentricular arrhythmias

Identifiers

PMID32556671
OpenAlexW3035875556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.